Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Department of Cancer Genetics and Genomics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Pharmacol Ther. 2022 Sep;237:108253. doi: 10.1016/j.pharmthera.2022.108253. Epub 2022 Jul 21.
Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor heterogeneity and lack of biomarkers are thought to be some of the most difficult challenges driving therapeutic resistance and relapse. This review will summarize current therapy for TNBC, studies in treatment resistance and relapse, including data from recent single cell sequencing. We will discuss changes in both the transcriptome and epigenome of TNBC, and we will review mechanisms regulating the immune microenvironment. Lastly, we will provide new perspective in patient stratification, and treatment options targeting transcriptome dysregulation and the immune microenvironment of TNBC patients.
三阴性乳腺癌（TNBC）是一种侵袭性亚型，其特征为广泛的肿瘤内异质性，并经常对治疗产生耐药性。肿瘤异质性和缺乏生物标志物被认为是导致治疗耐药和复发的最困难挑战之一。本综述将总结 TNBC 的当前治疗方法、治疗耐药和复发的研究，包括最近单细胞测序的数据。我们将讨论 TNBC 的转录组和表观基因组的变化，并综述调节免疫微环境的机制。最后，我们将提供新的视角，即针对 TNBC 患者转录组失调和免疫微环境的患者分层和治疗选择。
